| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Pietro Invernizzi | Q37842572 |
| Elena Prina | Q59879974 | ||
| Pier Maria Battezzati | Q40589790 | ||
| Carlo Selmi | Q42356913 | ||
| P2093 | author name string | Mauro Podda | |
| Andrea Crosignani | |||
| P2860 | cites work | Liver transplantation for primary biliary cirrhosis | Q79240270 |
| Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study | Q80556777 | ||
| Ondansetron and pruritus in chronic liver disease: a controlled study | Q80606942 | ||
| Primary biliary cirrhosis | Q81246142 | ||
| Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis | Q81513622 | ||
| Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites | Q82639990 | ||
| Polluting the pathogenesis of primary biliary cirrhosis | Q82640100 | ||
| Bone loss and reduced osteoblast function in primary biliary cirrhosis | Q93642995 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Effects of long-term rifampicin administration in primary biliary cirrhosis | Q28319860 | ||
| Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration | Q28334026 | ||
| Osteoporosis in primary biliary cirrhosis revisited | Q28343982 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis. | Q32064450 | ||
| Treatment of primary biliary cirrhosis with low-dose weekly methotrexate | Q33384106 | ||
| Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver | Q33526556 | ||
| Incidence of cancer in primary biliary cirrhosis: the Mayo experience | Q33601440 | ||
| Familial primary biliary cirrhosis in Hiroshima | Q33707458 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Primary biliary cirrhosis once rare, now common in the United Kingdom? | Q33869156 | ||
| Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited | Q34146325 | ||
| Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group | Q34408189 | ||
| Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients | Q34462959 | ||
| The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales | Q34476962 | ||
| Serum bilirubin: a prognostic factor in primary biliary cirrhosis | Q34494336 | ||
| Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality | Q34496270 | ||
| Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years | Q34932835 | ||
| Quality of life and everyday activities in patients with primary biliary cirrhosis | Q35142961 | ||
| Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence | Q35182259 | ||
| AGA technical review on osteoporosis in hepatic disorders. | Q35209520 | ||
| The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences | Q35348722 | ||
| Natural history of primary biliary cirrhosis. | Q35573903 | ||
| The epidemiology of primary biliary cirrhosis | Q35573904 | ||
| Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. | Q35594405 | ||
| Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis | Q35594898 | ||
| Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. | Q35596429 | ||
| Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort | Q35596580 | ||
| Opioid peptides and primary biliary cirrhosis | Q35706319 | ||
| Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis | Q35760198 | ||
| Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort | Q35760389 | ||
| Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis | Q35760984 | ||
| The natural history of PBC: has it changed? | Q36249680 | ||
| Systematic review and meta-analysis: D-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis--Cochrane Hepato-Biliary Group | Q36700785 | ||
| Spinal opiate analgesia and facial pruritus: a neural theory | Q36717326 | ||
| Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy | Q36798266 | ||
| Primary biliary cirrhosis: paradigm or paradox for autoimmunity | Q37637964 | ||
| The pruritus of cholestasis: from bile acids to opiate agonists | Q37879905 | ||
| Prediction of short-term survival with an application in primary biliary cirrhosis | Q39085766 | ||
| Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden | Q39317079 | ||
| Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis | Q39429100 | ||
| Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial | Q77609350 | ||
| Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial | Q78039888 | ||
| Prevalence of autoimmune liver disease in Alaska Natives | Q78309924 | ||
| The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis | Q45024371 | ||
| Quality of life in patients with primary biliary cirrhosis | Q45059665 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial | Q45309693 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| A controlled trial of ondansetron in the pruritus of cholestasis | Q46424983 | ||
| A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue | Q46509129 | ||
| Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans | Q46637413 | ||
| Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial | Q46714065 | ||
| Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | Q46775425 | ||
| Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment | Q46795010 | ||
| Effects of central administration of opioids on facial scratching in monkeys | Q48454564 | ||
| Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence | Q48496394 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. | Q49136167 | ||
| Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus | Q49138901 | ||
| Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis | Q49323238 | ||
| Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. | Q50535528 | ||
| Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. | Q50553464 | ||
| Epidemiology of primary biliary cirrhosis. | Q50588351 | ||
| Primary Biliary Cirrhosis in Estonia with Special Reference to Incidence, Prevalence, Clinical Features, and Outcome | Q50595131 | ||
| Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. | Q50628941 | ||
| Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. | Q50684179 | ||
| Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well-preserved liver function. | Q50711662 | ||
| The role of psychological factors in the fatigue of primary biliary cirrhosis. | Q50900931 | ||
| Primary biliary cirrhosis (PBC) in an European country--a description of death rates in The Netherlands (1979-1992). | Q50997570 | ||
| Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. | Q51107644 | ||
| Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. | Q51108387 | ||
| A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
| Intestinal calcium absorption and vitamin D status in chronic cholestatic liver disease. | Q51643224 | ||
| Inadequate dietary intake but not renal tubular acidosis is associated with bone demineralization in primary biliary cirrhosis. | Q51770188 | ||
| Fatigue is not a specific symptom in patients with primary biliary cirrhosis. | Q51933023 | ||
| Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis. | Q53190185 | ||
| Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. | Q53221825 | ||
| Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. | Q53527400 | ||
| Reduced heart rate variability and baroreflex sensitivity in primary biliary cirrhosis. | Q53778988 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Frequency of monosomy X in women with primary biliary cirrhosis. | Q55038191 | ||
| Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. | Q55041843 | ||
| Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. | Q55052049 | ||
| Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid | Q55174800 | ||
| Pruritic effect of bile salts. | Q55264876 | ||
| Primary biliary cirrhosis | Q56854243 | ||
| Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment | Q57226640 | ||
| Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity | Q57710875 | ||
| Osteoporosis in Primary Biliary Cirrhosis: A Randomized Trial of the Efficacy and Feasibility of Estrogen/Progestin | Q58311495 | ||
| Sertraline as a first-line treatment for cholestatic pruritus | Q61480066 | ||
| Familial primary biliary cirrhosis reassessed: a geographically-based population study | Q61633902 | ||
| Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study | Q61854318 | ||
| A prospective controlled trial of azathioprine in primary biliary cirrhosis | Q67479144 | ||
| A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results | Q67590480 | ||
| Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis | Q67926514 | ||
| Evaluation of colchicine therapy in primary biliary cirrhosis | Q68139571 | ||
| Factors of prognostic importance in primary biliary cirrhosis | Q68712203 | ||
| Unusual trihydroxy bile acids in the urine of patients treated with chenodeoxycholate, ursodeoxycholate or rifampicin and those with cirrhosis | Q68716620 | ||
| The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? | Q68886258 | ||
| Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids | Q68903834 | ||
| Clinical hepatology: profile of an urban, hospital-based practice | Q39432473 | ||
| Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England | Q39452020 | ||
| Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron | Q39476222 | ||
| Treatment of pruritus of primary biliary cirrhosis with rifampin | Q39511303 | ||
| Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial | Q39533520 | ||
| The geographical distribution of primary biliary cirrhosis in a well-defined cohort. | Q39587052 | ||
| Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. | Q39595436 | ||
| Relief of the pruritus of jaundice with a bile-acid sequestering resin | Q39597365 | ||
| Pathophysiology of Pruritus Associated With Elevated Bile Acid Levels in Serum | Q39920376 | ||
| Primary biliary cirrhosis: diagnosis, pathology and pathogenesis | Q40164416 | ||
| The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids | Q40513479 | ||
| Familial primary biliary cirrhosis | Q40634968 | ||
| The true impact of fatigue in primary biliary cirrhosis: a population study | Q40643274 | ||
| Epidemiology and natural history of primary biliary cirrhosis in a US community | Q40735092 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Endogenous opioids accumulate in plasma in a rat model of acute cholestasis | Q41127946 | ||
| Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. | Q41341706 | ||
| Pruritus in cholestasis: No direct causative role for bile acid retention | Q41634480 | ||
| Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial | Q41673941 | ||
| Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study | Q42551010 | ||
| A prospective trial of colchicine for primary biliary cirrhosis | Q42659809 | ||
| Fatigue in chronic cholestasis | Q43005119 | ||
| Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability | Q43475774 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration | Q43545407 | ||
| Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. | Q43734578 | ||
| Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial | Q43766090 | ||
| Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers | Q43954071 | ||
| The prevalence and clinical spectrum of primary biliary cirrhosis in a defined population. | Q43973385 | ||
| Randomized trial of chlorambucil for primary biliary cirrhosis. | Q44093311 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial | Q44110703 | ||
| Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease | Q44110715 | ||
| Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial | Q44256491 | ||
| The demography of primary biliary cirrhosis in Ontario, Canada | Q44439436 | ||
| Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease | Q44513824 | ||
| Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. | Q44573504 | ||
| Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis | Q44627887 | ||
| Primary biliary cirrhosis in Israel | Q44714188 | ||
| Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. | Q44778662 | ||
| Natural history of pruritus in primary biliary cirrhosis | Q44797529 | ||
| An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis | Q44930771 | ||
| Risk factors for primary biliary cirrhosis in a cohort of patients from the united states | Q44933098 | ||
| Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations | Q45010914 | ||
| Pathogenesis of steatorrhea in primary biliary cirrhosis | Q68940388 | ||
| The Presentation and Diagnosis of 100 Patients with Primary Biliary Cirrhosis | Q69302463 | ||
| A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report | Q69401293 | ||
| Risk factors and prognosis in primary biliary cirrhosis | Q69646317 | ||
| A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss | Q69721905 | ||
| Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin | Q69764185 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis | Q69903541 | ||
| A new treatment for primary biliary cirrhosis? | Q69908808 | ||
| Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease | Q69971289 | ||
| Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry | Q70368433 | ||
| Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial | Q70542319 | ||
| Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis | Q70670252 | ||
| Time course of histological progression in primary biliary cirrhosis | Q70869710 | ||
| Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis | Q71035932 | ||
| Primary biliary cirrhosis: an epidemiological study | Q71354203 | ||
| Intraspinal opiates and itching: a new reflex? | Q71600424 | ||
| Stimulation of bile acid 6 alpha-hydroxylation by rifampin | Q71603505 | ||
| End-stage primary biliary cirrhosis in a first generation migrant south Asian population | Q71645499 | ||
| A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group | Q71748735 | ||
| Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis | Q72036049 | ||
| Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits | Q72036541 | ||
| Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis | Q72164989 | ||
| Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine | Q72210545 | ||
| Improvement of cholestatic pruritus by ondansetron | Q72218628 | ||
| Ondansetron for pruritus due to cholestasis | Q72379137 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Primary biliary cirrhosis--a revised clinical spectrum | Q72471842 | ||
| Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? | Q72511247 | ||
| Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment | Q72688424 | ||
| Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years | Q72727069 | ||
| The pruritus of cholestasis | Q72761756 | ||
| Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial | Q73026352 | ||
| A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis | Q73118377 | ||
| Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study | Q73130933 | ||
| Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment | Q73316077 | ||
| Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis | Q73319901 | ||
| Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial | Q73330566 | ||
| Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | Q73401694 | ||
| Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years | Q73475924 | ||
| Primary biliary cirrhosis with pruritus in India | Q73566881 | ||
| The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone | Q73574823 | ||
| Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines | Q73584928 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| An exploratory population-based case-control study of primary biliary cirrhosis | Q73746110 | ||
| Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis | Q73979498 | ||
| Hyperlipidemia in Chronic Cholestatic Liver Disease | Q74256081 | ||
| Open-label trial of oral nalmefene therapy for the pruritus of cholestasis | Q74310569 | ||
| Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy | Q77058192 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 3313-3327 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Clinical features and management of primary biliary cirrhosis | |
| P478 | volume | 14 |
| Q35724515 | A woman with recent jaundice and pruritus |
| Q40589408 | ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression |
| Q34383331 | Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI. |
| Q58130994 | Autoimmunerkrankungen der Leber |
| Q44162573 | Complete spectrum of AMA-M2 positive liver disease in north India |
| Q44247097 | Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba |
| Q91642039 | Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies |
| Q37418054 | Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. |
| Q53019283 | Immunologic derangement preceding clinical autoimmunity. |
| Q37877588 | Immunological diseases of the pancreatico-hepatobiliary system: update on etiopathogenesis and cross-sectional imaging findings |
| Q40707802 | Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: a population-based study. |
| Q35043760 | Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study |
| Q26853145 | Primary biliary cirrhosis and liver transplantation |
| Q36085576 | Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice |
Search more.